Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It went up on hype and down with a lack of hype. I think every single MMJ play did it including everyone's beloved GWPH. Not from huge amounts of dilution.
We are one of the few, maybe the only, mmj bio pharma company to have a product ready to hit shelves worldwide with amazing growth potential year over year due to all the countries making it legal. Throw the orphan drug status in there for MM and we have ourselves a company that will reach a billion dollar market cap sooner then later! GLTA
This stock will be a work horse longterm Gary. Selling now with sales starting before year end and MM study continuing to make progress makes little sense. We are one of the few bio pharma mmj companies out there that are not dependent upon what the US does. Once we get product out there other then the US will help investors realize we are a well balanced company. Emerging markets are popping up monthly worldwide!
Crosslisting will help stabilize and or rise this stock price too, again, it takes time!
PATIENCE +OWCP= FINACIAL FREEDOM
Email your senators people, make sure your voice is heard! I've emailed my senators in my state and have received responses back. I can tell you my senator in Minnesota is working hard to keep mmj legal!!! Make your voice heard, it truly can make a difference!
Very few mmj bio pharma companies are even close to taking a drug to orphan drug. Owcp knows there MM drug works, now there just determining the best delivery system for it which ends in q3. We are probably months, not years from taking this to orphan drug status.
Staying strong here at these levels, great time to buy and accumulate. Crosslisting will be happening, cream customers and partnerships will be announced! Multiple myeloma study delivery system ends in Q3 which is part of preparing it to move to orphan drug. An Announcement of this moving to orphan drug would be huge!!
It's a good time to buy IMO also! We should be getting more positive news in July here to start solidifying what we already know! We will test recent highs and beyond as news of more stores starts to roll in!
This is a great part of a recent PR. There should be several agreements over the next few months on who and where we will be selling the cream to! Canada news will be coming along with the rest of Europe!
Commenting on the filing of the patent application, Mr. Mordechai Bignitz, Chairman and CEO of OWC Pharmaceutical Research, stated, "After we announced the highlights of our pre-clinical efficacy study for our active, cannabinoid-based topical cream, starting with psoriasis, we received numerous inquiries from firms and organizations worldwide interested in purchasing the cream or initiating commercial or scientific collaboration with OWCP. The need to fully protect our intellectual property limited our ability to provide these potential customers and partners with our proprietary data. This proprietary data now includes specifics regarding the formulation of the cream, which consists of cannabinoids and other compounds that facilitate the efficient delivery of the product to infected areas. The filing of this patent application also enables us to discuss with potential customers and partners, the requirements for manufacturing the cream in accordance with the highest global standards that comply with international protocols, and includes specifics regarding required equipment and systems. We look forward to announcing a more specific plan of product launch details in due course."
Stay in the game here peeps...... negative attention is actually positive attention! The only one who looks after your self interest is yourself!
OWCP IS FILING THROUGH THE SEC
IF YOU BELIEVE THIS SYSTEM DOES NOT WORK, THEN WE HAVE SOME BIG PROBLEMS. TAKE IT UP WITH THE SEC. TO FIND OUT IF OWCP FILINGS ARE REAL!
This is part of why R&d costs are so small, Sheba has a small right, or Royalties I will say. For doing certain studies. This means Sheba is a believer in there study. Otherwise they would be taking a substantial hit in the long run if the products don't work. It's right in there filings. I recommend to all not to respond to patent talks any longer as it's been hammered on now for 3 months. If an investor wants to buy in he should not be taking the advice from self appointed patent experts and go by the companies filings that are LEGALLY bound to the SEC.
This is strait out of there filings about R&d
While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis.
Pursuant to the collaboration agreements, we are expected to pay Sheba $170,000 for conducting the multiple myeloma trial between the 3rd quarter of 2015 and the second quarter of 2016. In addition, we commenced pre-clinical studies on the treatment of psoriasis during the second quarter of 2016. Pursuant to the collaboration agreements, we are obliged to pay Sheba $85,000 throughout 2017 for conducting the safety study for the cream. We currently have the financial resources to fund our current obligations under these agreements,
This CFO looks good, but not the person I was hearing would be taking the reigns.
It's awesome to see his Nasdaq experience!
This is a big reason longs invested here months ago! Great DD to all longs and future longs that already knew this!!
http://host.madison.com/business/investment/markets-and-stocks/forget-the-u-s-marijuana-market----there/article_d7702424-c20b-5e1f-9987-70105d72cc8a.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share
Owcp has a hired a Top Notch Patent Lawyer, never take advice from a self appointed wanna be patent expert. I've personally spoken to there Laywer and firm and this isn't there first rabbit hunt! They will get it done along with other patents!
Israelis know how to get it done! A little unknown fact is they are leaders in start up companies! I will put my money on them to kick start this new industry!
http://nocamels.com/2016/10/israel-second-most-innovative-country/
This is why a great cfo is needed, not just a good one!
http://www.investopedia.com/ask/answers/04/042204.asp
I think in any new industry it's important to give investors a sense of security. Security can come in different ways, and one main one is who's doing all the deals and helping lead the charge to be successful. If we get a CFO who is really unknown without a track record of success, expect business to happen as usual. If someone comes in with lots of connections and experience in the business world, this company becomes a workhorse longterm. A CFO can come from any industry, the CEO should have a healthcare background. Negotiations for a CEO are still taking place for our subsidiary.
Growth potential here is explosive! Although the US is behind the eight ball here, year over year growth worldwide is happening monthly as more countries legalize it for medical use. Owcp knows this and will bring in a big time cfo to run the company for world wide sales....it's about to get real here!
I agree, maybe even like last week where they drop an 8-k and the PR would be the following day, which would be Wednesday morning. Here's a good article about the expanding medical marijuana business and a good reason to be invested here with there world wide exposure.
http://host.madison.com/business/investment/markets-and-stocks/forget-the-u-s-marijuana-market----there/article_d7702424-c20b-5e1f-9987-70105d72cc8a.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share
The patent that is expected to be approved has nothing to do with the news.
I wonder if the cfo will not be real to???? Ha ha you have an awesome fourth weekend!
Best of luck to you:)
You timed it just right, nice job and glad your onboard!
Big news about to come out..... its going to be a rough ride for shorts from here on out:)!!!
That's what he's saying and is correct, because of the agreement. Although not all study's are set up that way...
This is in there filings, everyone just has to take the time to read them!!!
While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis.
Pursuant to the collaboration agreements, we are expected to pay Sheba $170,000 for conducting the multiple myeloma trial between the 3rd quarter of 2015 and the second quarter of 2016. In addition, we commenced pre-clinical studies on the treatment of psoriasis during the second quarter of 2016. Pursuant to the collaboration agreements, we are obliged to pay Sheba $85,000 throughout 2017 for conducting the safety study for the cream.
Sheba has a small right to the intellectual property rights on the Psoriasis study that took place. That's there payment, says a lot that they think this will be a great product and will recoup there R&d there doing. This also applies to the fibromyalgia study. Put that one to rest now.
I will pinch the good doctor and his crew when I meet them in a few months, if they say , "OUCH " , we will know they're real, until then do not invest in this company! ......hand slap to my forehead:)
Might happen sooner then you think, I know California is a priority to them. Things are getting more and more real here in OWCP land!
Wow how time flies! The end of Q3 is Really not that far away now. Along with that will conclude the delivery method phase of our MM study. Orphan drug is closing fast:)
PETACH TIKVA, Israel, May 3, 2017 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future the planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated "after in-depth and extensive review and assessment of the study's results accumulated so far, OWC's research committee determined that the medical and scientific accepted multiple myeloma mice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
The initial OWC study was conducted at the Israeli-renowned Academic Medical Center (affiliated with Tel-Aviv University) using three repetitive tests on the effect of OWC's proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results from our earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Mordechai Bignitz Chairman and CEO
Email: mordechai.bignitz@owcpharma.com
Tel: +972-(0)3-770-8526
SOURCE OWC Pharmaceutical Research Corp.
OWCP + patience = financial freedom.
Not true, they are trying to hit a couple of the heavily populated states due to state to state restrictions. California would be high on there list to sell cream and other products.
Yes sir, some exciting times ahead! This patent application was huge!
You are spot on:) long and strong here!
The patent bandit is sound asleep. Never mind the noise behind the curtains here longs and newbies.
We all should be pleased there is so much interest in this stock by longs and shorts! It fairs well for the longterm investors!
I've been pounding on this, the cfo there bringing in will prove to the investment community where Owcp is heading. That announcement comes as early as Friday or Monday!
Always, always refer to the companies official filings for the truth, not self appointed anylysts!
All these form threes after cfo resigns and new one begins...... maybe a large share transfer about to take place to pay for him to join us...... he must be a big deal!:)
The announcement of the new CFO will explain to people here the direction the company is intending on heading:)
Multiple myeloma updates will be coming forward also, sublingual tablet, etc. lots in the works!
Anyone who wants to see study's or official filings with Sheba and costs, go on there website. There is a whole pile of official filings through the SEC. That is legal and what you should follow. Never follow a self appointed individual who says otherwise.
Long and strong here, the official filings and fundementals are all there.
You are pretty spot on, it's starting to act like a big boy stock here. Longterm this is definitely golden. I'm here for there multiple myeloma study amongst other things the company is doing. We are worldwide and the possibilities are endless here!
CFO announcement will help define where the company is planning on heading in the upcoming years. Lots of things to be excited for, and they all take time.
Best of luck all!
This is just the beginning, rumblings of a big league cfo coming to Owcp are getting louder! Longterm outlook here looks amazing!
Make a position today and hold it, more big news to follow this!
This is just the beginning, a lot of great things to be announced in the next few months!